Paris, October 22, 2007 - BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, said it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate (BA 015 program), at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30... BioAlliance Pharma's Press Release [PDF] - Communiqué de Presse de BioAlliance Pharma en français (PDF]-
Tuesday, October 23, 2007
BioAlliance Pharma, promising in vivo results for a New Entity
Paris, October 22, 2007 - BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, said it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate (BA 015 program), at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30... BioAlliance Pharma's Press Release [PDF] - Communiqué de Presse de BioAlliance Pharma en français (PDF]-
